Successful of Autologous Hematopoietic Stem Cell Mobilization With Plerixafor Combined With G-Csf in Pediatric Neuroblastoma Patients, a Single Center Experience

Successful of Autologous Hematopoietic Stem Cell Mobilization With Plerixafor Combined With G-Csf in Pediatric Neuroblastoma Patients, a Single Center Experience Publisher Pubmed

Jafari L¹ ; Hematyar F¹ ; Karamlou Y² ; Alipour N³ ; Mohseni R¹ ; Jafari F¹ ; Nikfetrat Z¹ ; Behfar M¹ ; Hamidieh AA¹

Show Affiliations

1. Pediatric Cell and Gene Therapy Research Centre, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran
2. Center for Gene and Cell Therapy, Washington University of St. Louis, Bone Marrow Transplantation of Washington DC, United States
3. Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Transfusion and Apheresis Science Published:2025

Abstract

Background: Neuroblastoma (NB) is the most common extracranial solid tumor in pediatric. In highrisk NB patients, the 5-year overall survival rate (OS) remains a stark < 50 % with conventional therapies. Autologous hematopoietic stem cell transplantation with high dose chemotherapies was used in poor prognosis and high-risk patients.Today, Plerixafor is used to increase stem cells mobilization in patients who are candidates for autologous transplantation. Objective: This study examined safety and efficacy Plerixafor is administered as a subcutaneous injection in pediatric NB patients for stem cell mobilization Study Design: A cohort of 19 pediatric neuroblastoma (NB) patients underwent autologous hematopoietic stem cell transplantation (HSCT) between February 2017 and April 2019, receiving G-CSF mobilization only. Subsequently, 37 NB patients underwent HSCT between December 2019 and October 2023, receiving both G-CSF and plerixafor for mobilization (auto-HSCT). Results: The final product CD34 cell dose /kg was evidently higher in combination group at 5.363 ± 4.243 vs. G-CSF group at 2.827 ± 3.586 × 106(P value= 0.001). Neutrophils and platelet engraftment were occurred sooner in combination group compared with G-CSF group. The 1-year overall survival (OS) rate for the G-CSF and G-CSF-and-plerixafor combination group was 70.8 % and 63.3 %, respectively (P = 0.874). No statistically significant difference in OS or disease-free survival (DFS) was observed between the two treatment groups. Conclusion: The results show that plerixafor may be safe and effective in NB pediatric patients in routine clinical practice. It was well tolerated in NB patients and no specific side effects were observed. It was not associated with improved survival. © 2025

Style	Citing Format
MLA	Jafari L, et al.. "Successful of Autologous Hematopoietic Stem Cell Mobilization With Plerixafor Combined With G-Csf in Pediatric Neuroblastoma Patients, a Single Center Experience." Transfusion and Apheresis Science, vol. 64, no. 1, 2025, pp. -.
APA	Jafari L, Hematyar F, Karamlou Y, Alipour N, Mohseni R, Jafari F, Nikfetrat Z, Behfar M, Hamidieh AA (2025). Successful of Autologous Hematopoietic Stem Cell Mobilization With Plerixafor Combined With G-Csf in Pediatric Neuroblastoma Patients, a Single Center Experience. Transfusion and Apheresis Science, 64(1), -.
Chicago	Jafari L, Hematyar F, Karamlou Y, Alipour N, Mohseni R, Jafari F, Nikfetrat Z, Behfar M, Hamidieh AA. "Successful of Autologous Hematopoietic Stem Cell Mobilization With Plerixafor Combined With G-Csf in Pediatric Neuroblastoma Patients, a Single Center Experience." Transfusion and Apheresis Science 64, no. 1 (2025): -.
Harvard	Jafari L et al. (2025) 'Successful of Autologous Hematopoietic Stem Cell Mobilization With Plerixafor Combined With G-Csf in Pediatric Neuroblastoma Patients, a Single Center Experience', Transfusion and Apheresis Science, 64(1), pp. -.
Vancouver	Jafari L, Hematyar F, Karamlou Y, Alipour N, Mohseni R, Jafari F, et al.. Successful of Autologous Hematopoietic Stem Cell Mobilization With Plerixafor Combined With G-Csf in Pediatric Neuroblastoma Patients, a Single Center Experience. Transfusion and Apheresis Science. 2025;64(1):-.
BibTex	@article{ author = {Jafari L and Hematyar F and Karamlou Y and Alipour N and Mohseni R and Jafari F and Nikfetrat Z and Behfar M and Hamidieh AA}, title = {Successful of Autologous Hematopoietic Stem Cell Mobilization With Plerixafor Combined With G-Csf in Pediatric Neuroblastoma Patients, a Single Center Experience}, journal = {Transfusion and Apheresis Science}, volume = {64}, number = {1}, pages = {-}, year = {2025} }
RIS	TY - JOUR AU - Jafari L AU - Hematyar F AU - Karamlou Y AU - Alipour N AU - Mohseni R AU - Jafari F AU - Nikfetrat Z AU - Behfar M AU - Hamidieh AA TI - Successful of Autologous Hematopoietic Stem Cell Mobilization With Plerixafor Combined With G-Csf in Pediatric Neuroblastoma Patients, a Single Center Experience JO - Transfusion and Apheresis Science VL - 64 IS - 1 SP - EP - PY - 2025 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract